Study 30 of 31Retatrutide (LY3437943) literatureLancet (London, England)Top journal2026
Retatrutide in adults with obesity and type 2 diabetes: what have we learned from TRIUMPH-2?
Not reported in abstract.
Where it sits
this study against the rest of the retatrutide (ly3437943) corpus13
Preclinical · this one
7
Observational
0
Open-label
5
Randomised
6
Reviews
Summary and findings
Not reported in abstract.
How much of this paper we could read: title only (0.10). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
2026
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
Not reported in abstract.
Elsewhere in the Retatrutide (LY3437943) corpus
DUnapproved GLP-1 Drugs Retatrutide and Zenagamtide Sold Online Are No Bargain.JAMA · 2026—DRetatrutide trial: Triple action jab can cause weight loss of up to 25%, results suggest.BMJ (Clinical research ed.) · 2026—AThe First Triple Agonist for Antiobesity: Retatrutide.Cardiology in review · 2024 · Not reported in abstract.reviewDThe First Triple Agonist for Antiobesity: Retatrutide.Cardiology in review · 2026 · Not reported in abstract.reviewARetatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.Lancet (London, England) · 2026 · -18.8% bodyweight change at week 80 with retatrutide 12 mg, n=287, p<0.0001.HumanARetatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity.The New England journal of medicine · 2026 · -25.0% mean percent change in body weight for 12 mg dose vs -3.9% placebo, P<0.001Human